1
|
Kovács F, Huliák I, Árva H, Kiricsi M, Erdős D, Kocsis M, Takács G, Balogh GT, Frank É. Medicinal-Chemistry-Driven Approach to 2-Substituted Benzoxazole-Estradiol Chimeras: Synthesis, Anticancer Activity, and Early ADME Profile. ChemMedChem 2023; 18:e202300352. [PMID: 37727903 DOI: 10.1002/cmdc.202300352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2023] [Revised: 09/12/2023] [Accepted: 09/19/2023] [Indexed: 09/21/2023]
Abstract
The efficient synthesis of novel estradiol-based A-ring-fused oxazole derivatives, which can be considered as benzoxazole-steroid domain-integrated hybrids containing a common benzene structural motif, is described. The target compounds were prepared from steroidal 2-aminophenol precursors by heterocycle formation or functional group interconversion (FGI) strategies. According to 2D projection-based t-distributed stochastic neighbor embedding (t-SNE), the novel molecules were proved to represent a new chemical space among steroid drugs. They were characterized based on critical physicochemical parameters using in silico and experimental data. The performance of the compounds to inhibit cell proliferation was tested on four human cancer cell lines and non-cancerous cells. Further examinations were performed to reveal IC50 and lipophilic ligand efficiency (LLE) values, cancer cell selectivity, and apoptosis-triggering features. Pharmacological tests and LLE metric revealed that some derivatives, especially the 2-(4-ethylpiperazin-1-yl)oxazole derivative exhibit strong anticancer activity and trigger the apoptosis of cancer cells with relatively low promiscuity risk similarly to the structurally most closely-related and intensively studied anticancer agent, 2-methoxy-estradiol.
Collapse
Affiliation(s)
- Ferenc Kovács
- Department of Molecular and Analytical Chemistry, University of Szeged, Dóm tér 7-8, 6720, Szeged, Hungary
| | - Ildikó Huliák
- Department of Biochemistry and Molecular Biology, Doctoral School of Biology, University of Szeged, Közép fasor 52, 6726, Szeged, Hungary
| | - Hédi Árva
- Department of Biochemistry and Molecular Biology, Doctoral School of Biology, University of Szeged, Közép fasor 52, 6726, Szeged, Hungary
| | - Mónika Kiricsi
- Department of Biochemistry and Molecular Biology, Doctoral School of Biology, University of Szeged, Közép fasor 52, 6726, Szeged, Hungary
| | - Dóra Erdős
- Department of Chemical and Environmental Process Engineering, Budapest University of Technology and Economics, Műegyetem rkp. 3, 1111, Budapest, Hungary
| | - Marianna Kocsis
- Department of Molecular and Analytical Chemistry, University of Szeged, Dóm tér 7-8, 6720, Szeged, Hungary
| | - Gergely Takács
- Department of Chemical and Environmental Process Engineering, Budapest University of Technology and Economics, Műegyetem rkp. 3, 1111, Budapest, Hungary
- Mcule.com Kft., Bartók Béla út 105-113, 1115, Budapest, Hungary
| | - György T Balogh
- Department of Chemical and Environmental Process Engineering, Budapest University of Technology and Economics, Műegyetem rkp. 3, 1111, Budapest, Hungary
- Department of Pharmaceutical Chemistry, Semmelweis University, Hőgyes E. 9, 1085, Budapest, Hungary
| | - Éva Frank
- Department of Molecular and Analytical Chemistry, University of Szeged, Dóm tér 7-8, 6720, Szeged, Hungary
| |
Collapse
|
2
|
Latysheva AS, Zolottsev VA, Veselovsky AV, Scherbakov KA, Morozevich GE, Zhdanov DD, Novikov RA, Misharin AY. Oxazolinyl derivatives of androst-16-ene as inhibitors of CYP17A1 activity and prostate carcinoma cells proliferation: Effects of substituents in oxazolinyl moiety. J Steroid Biochem Mol Biol 2023; 230:106280. [PMID: 36870373 DOI: 10.1016/j.jsbmb.2023.106280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/27/2022] [Revised: 03/01/2023] [Accepted: 03/02/2023] [Indexed: 03/06/2023]
Abstract
Steroid derivatives modified with nitrogen containing heterocycles are known to inhibit activity of steroidogenic enzymes, decrease proliferation of cancer cells and attract attention as promising anticancer agents. Specifically, 2'-(3β-hydroxyandrosta-5,16-dien-17-yl)-4',5'-dihydro-1',3'-oxazole 1a potently inhibited proliferation of prostate carcinoma cells. In this study we synthesized and investigated five new derivatives of 3β-hydroxyandrosta-5,16-diene comprising 4'-methyl or 4'-phenyl substituted oxazolinyl cycle 1 (b-f). Docking of compounds 1 (a-f) to CYP17A1 active site revealed that the presence of substitutents at C4' atom in oxazoline cycle, as well as C4' atom configuration, significantly affect docking poses of compounds in the complexes with enzyme. Testing of compounds 1 (a-f) as CYP17A1 inhibitors revealed that the only compound 1a, comprising unsubstituted oxazolinyl moiety, demonstrated strong inhibitory activity, while other compounds 1 (b-f) were slightly active or non active. Compounds 1 (a-f) efficiently decreased growth and proliferation of prostate carcinoma LNCaP and PC-3 cells at 96 h incubation; the effect of compound 1a was the most powerful. Compound 1a efficiently stimulated apoptosis and caused PC-3 cells death, that was demonstrated by a direct comparison of pro-apoptotic effects of compound 1a and abiraterone.
Collapse
Affiliation(s)
- Alexandra S Latysheva
- V.N. Orekhovich Institute of Biomedical Chemistry, 10, Pogodinskaya street, 119435 Moscow, Russia
| | - Vladimir A Zolottsev
- V.N. Orekhovich Institute of Biomedical Chemistry, 10, Pogodinskaya street, 119435 Moscow, Russia; RUDN University, 6, Miklukho-Maklaya street, 117198 Moscow, Russia.
| | - Alexander V Veselovsky
- V.N. Orekhovich Institute of Biomedical Chemistry, 10, Pogodinskaya street, 119435 Moscow, Russia
| | - Kirill A Scherbakov
- V.N. Orekhovich Institute of Biomedical Chemistry, 10, Pogodinskaya street, 119435 Moscow, Russia
| | - Galina E Morozevich
- V.N. Orekhovich Institute of Biomedical Chemistry, 10, Pogodinskaya street, 119435 Moscow, Russia
| | - Dmitry D Zhdanov
- V.N. Orekhovich Institute of Biomedical Chemistry, 10, Pogodinskaya street, 119435 Moscow, Russia; RUDN University, 6, Miklukho-Maklaya street, 117198 Moscow, Russia
| | - Roman A Novikov
- V.A. Engelhardt Institute of Molecular Biology RAS, 32, Vavilov street, Moscow, Russia
| | - Alexander Y Misharin
- V.N. Orekhovich Institute of Biomedical Chemistry, 10, Pogodinskaya street, 119435 Moscow, Russia
| |
Collapse
|
3
|
Design and Synthesis of New Agents for Prostate Cancer Treatment Inspired by Steroidal CYP17 A1 Inhibitors. ChemistrySelect 2022. [DOI: 10.1002/slct.202203393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
|
4
|
Synthesis and Biological Evaluation of New Isoxazolyl Steroids as Anti-Prostate Cancer Agents. Int J Mol Sci 2022; 23:ijms232113534. [DOI: 10.3390/ijms232113534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2022] [Revised: 10/28/2022] [Accepted: 11/02/2022] [Indexed: 11/09/2022] Open
Abstract
Steroids with a nitrogen-containing heterocycle in the side chain are known as effective inhibitors of androgen signaling and/or testosterone biosynthesis, thus showing beneficial effects for the treatment of prostate cancer. In this work, a series of 3β-hydroxy-5-ene steroids, containing an isoxazole fragment in their side chain, was synthesized. The key steps included the preparation of Weinreb amide, its conversion to acetylenic ketones, and the 1,2- or 1,4-addition of hydroxylamine, depending on the solvent used. The biological activity of the obtained compounds was studied in a number of tests, including their effects on 17α-hydroxylase and 17,20-lyase activity of human CYP17A1 and the ability of selected compounds to affect the downstream androgen receptor signaling. Three derivatives diminished the transcriptional activity of androgen receptor and displayed reasonable antiproliferative activity. The candidate compound, 24j (17R)-17-((3-(2-hydroxypropan-2-yl)isoxazol-5-yl)methyl)-androst-5-en-3β-ol, suppressed the androgen receptor signaling and decreased its protein level in two prostate cancer cell lines, LNCaP and LAPC-4. Interaction of compounds with CYP17A1 and the androgen receptor was confirmed and described by molecular docking.
Collapse
|
5
|
Huo H, Li G, Shi B, Li J. Recent advances on synthesis and biological activities of C-17 aza-heterocycle derived steroids. Bioorg Med Chem 2022; 69:116882. [PMID: 35749841 DOI: 10.1016/j.bmc.2022.116882] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2022] [Revised: 05/15/2022] [Accepted: 06/08/2022] [Indexed: 11/02/2022]
Abstract
Steroids modification for improving their biological activities is one of the most efficient and fruitful methods to develop novel medicines. Steroids with aza-heterocycles attaching to the C-17 owing various biological activities have received great attentions and some of the compounds are developed successfully as drugs. In this review, the research of the syntheses and biological activities of steroids bearing various aza-heterocycles published in the last 8 years is assembled, and some important structure-activity relationships (SARs) of active compounds are presented. According to the analysis of the literatures and our experiences in this field, the potential of aza-heterocyclic steroids as medicinal drugs is proposed.
Collapse
Affiliation(s)
- Haibo Huo
- Department of Life Sciences, Changzhi University, Changzhi 046011, Shanxi, China
| | - Guixia Li
- Department of Basic Medicine, Changzhi Medical College, Changzhi, China
| | - Baojun Shi
- College of Plant Protection, Northwest A&F University, Yangling 712100, Shaanxi, China
| | - Jian Li
- Department of Life Sciences, Changzhi University, Changzhi 046011, Shanxi, China; Department of Chemistry, Changzhi University, Changzhi 046011, Shanxi, China.
| |
Collapse
|
6
|
An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer. Int J Mol Sci 2021; 22:ijms22042124. [PMID: 33672769 PMCID: PMC7924596 DOI: 10.3390/ijms22042124] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2021] [Revised: 02/17/2021] [Accepted: 02/17/2021] [Indexed: 12/31/2022] Open
Abstract
Traditional endocrine therapy for prostate cancer (PCa) has been directed at suppression of the androgen receptor (AR) signaling axis since Huggins et al. discovered that diethylstilbestrol (DES; an estrogen) produced chemical castration and PCa tumor regression. Androgen deprivation therapy (ADT) still remains the first-line PCa therapy. Insufficiency of ADT over time leads to castration-resistant PCa (CRPC) in which the AR axis is still active, despite castrate levels of circulating androgens. Despite the approval and use of multiple generations of competitive AR antagonists (antiandrogens), antiandrogen resistance emerges rapidly in CRPC due to several mechanisms, mostly converging in the AR axis. Recent evidence from multiple groups have defined noncompetitive or noncanonical direct binding sites on AR that can be targeted to inhibit the AR axis. This review discusses new developments in the PCa treatment paradigm that includes the next-generation molecules to noncanonical sites, proteolysis targeting chimera (PROTAC), or noncanonical N-terminal domain (NTD)-binding of selective AR degraders (SARDs). A few lead compounds targeting each of these novel noncanonical sites or with SARD activity are discussed. Many of these ligands are still in preclinical development, and a few early clinical leads have emerged, but successful late-stage clinical data are still lacking. The breadth and diversity of targets provide hope that optimized noncanonical inhibitors and/or SARDs will be able to overcome antiandrogen-resistant CRPC.
Collapse
|
7
|
Chernyshov VV, Yarovaya OI, Vatsadze SZ, Borisevich SS, Trukhan SN, Gatilov YV, Peshkov RY, Eltsov IV, Martyanov ON, Salakhutdinov NF. Unexpected Ring Opening During the Imination of Camphor‐Type Bicyclic Ketones. European J Org Chem 2020. [DOI: 10.1002/ejoc.202001397] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Vladimir V. Chernyshov
- N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS 9 Acad. Lavrentiev Ave. 630090 Novosibirsk Russian Federation
- Novosibirsk State University Pirogova St. 1 630090 Novosibirsk Russian Federation
| | - Olga I. Yarovaya
- N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS 9 Acad. Lavrentiev Ave. 630090 Novosibirsk Russian Federation
- Novosibirsk State University Pirogova St. 1 630090 Novosibirsk Russian Federation
| | - Sergey Z. Vatsadze
- N.D. Zelinsky Institute of Organic Chemistry Russian Academy of Sciences Leninski pr., 47 119991 Moscow Russian Federation
| | - Sophia S. Borisevich
- Laboratory of Chemical Physics Ufa Institute of Chemistry Ufa Federal Research Center Russian Academy of Sciences 71 Octyabrya pr. 450054 Ufa Russian Federation
| | - Sergey N. Trukhan
- Novosibirsk State University Pirogova St. 1 630090 Novosibirsk Russian Federation
- Boreskov Institute of Catalysis SB RAS 5 Acad. Lavrentiev Ave. 630090 Novosibirsk Russian Federation
| | - Yuri V. Gatilov
- N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS 9 Acad. Lavrentiev Ave. 630090 Novosibirsk Russian Federation
- Novosibirsk State University Pirogova St. 1 630090 Novosibirsk Russian Federation
| | - Roman Yu. Peshkov
- Novosibirsk State University Pirogova St. 1 630090 Novosibirsk Russian Federation
| | - Ilia V. Eltsov
- Novosibirsk State University Pirogova St. 1 630090 Novosibirsk Russian Federation
| | - Oleg N. Martyanov
- Novosibirsk State University Pirogova St. 1 630090 Novosibirsk Russian Federation
- Boreskov Institute of Catalysis SB RAS 5 Acad. Lavrentiev Ave. 630090 Novosibirsk Russian Federation
| | - Nariman F. Salakhutdinov
- N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS 9 Acad. Lavrentiev Ave. 630090 Novosibirsk Russian Federation
- Novosibirsk State University Pirogova St. 1 630090 Novosibirsk Russian Federation
| |
Collapse
|
8
|
Ghoshal T, Patel TM. Anticancer activity of benzoxazole derivative (2015 onwards): a review. FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES 2020. [DOI: 10.1186/s43094-020-00115-0] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Abstract
Background
According to the report published recently by the World Health Organization, the number of cancer cases in the world will increase to 22 million by 2030. So the anticancer drug research and development is taking place in the direction where the new entities are developed which are low in toxicity and are with improved activity. Benzoxazole and its derivative represent a very important class of heterocyclic compounds, which have a diverse therapeutic area. Recently, many active compounds synthesized are very effective; natural products isolated with benzoxazole moiety have also shown to be potent towards cancer.
Main text
In the last few years, many research groups have designed and developed many novel compounds with benzoxazole as their backbone and checked their anticancer activity. In the review article, the recent developments (mostly after 2015) made in the direction of design and synthesis of new scaffolds with very potent anticancer activity are briefly described. The effect of various heterocycles attached to the benzoxazole and their effect on the anticancer activity are thoroughly studied and recorded in the review.
Conclusion
These compiled data in the article will surely update the scientific community with the recent development in this area and will provide direction for further research in this area.
Collapse
|
9
|
Yan X, Wen J, Zhou L, Fan L, Wang X, Xu Z. Current Scenario of 1,3-oxazole Derivatives for Anticancer Activity. Curr Top Med Chem 2020; 20:1916-1937. [PMID: 32579505 DOI: 10.2174/1568026620666200624161151] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2020] [Revised: 05/06/2020] [Accepted: 05/21/2020] [Indexed: 02/07/2023]
Abstract
Cancer, which has been cursed for human beings for long time is considered as one of the
leading causes of morbidity and mortality across the world. In spite of different types of treatments
available, chemotherapy is still deemed as a favored treatment for the cancer. Unfortunately, many currently
accessible anticancer agents have developed multidrug resistance along with fatal adverse effects.
Therefore, intensive efforts have been made to seek for new active drugs with improved anticancer efficacy
and reduced adverse effects. In recent years, the emergence of heterocyclic ring-containing anticancer
agents has gained a great deal of attention among medicinal chemists. 1,3- oxazole is a versatile
heterocyclic compound, and its derivatives possess broad-spectrum pharmacological properties, including
anticancer activity against both drug-susceptible, drug-resistant and even multidrug-resistant cancer
cell lines through multiple mechanisms. Thus, the 1,3-oxazole moiety is a useful template for the development
of novel anticancer agents. This review will provide a comprehensive overview of the recent
advances on 1,3-oxazole derivatives with potential therapeutic applications as anticancer agents, focus
on the chemical structures, anticancer activity, and mechanisms of action.
Collapse
Affiliation(s)
- Xinjia Yan
- Department of Pharmacy, The 967th Hospital of Joint Logistic Support Force of PLA, Dalian, China
| | - Jing Wen
- College of Pharmacy, Harbin University of Commerce, Harbin, China
| | - Lin Zhou
- Department of Pharmacy, The 967th Hospital of Joint Logistic Support Force of PLA, Dalian, China
| | - Lei Fan
- Department of Pharmacy, The 967th Hospital of Joint Logistic Support Force of PLA, Dalian, China
| | - Xiaobo Wang
- Department of Pharmacy, The 967th Hospital of Joint Logistic Support Force of PLA, Dalian, China
| | - Zhi Xu
- College of Pharmaceutical Sciences, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China
| |
Collapse
|